The relationship between doctors and medical or company representatives is an ancient practice in which the primary objective of the company representative is to directly inform the medical profession about the company's products. There is nothing wrong with this practice, but it becomes situational when the medical representative is offered financial or company salary policy incentives. Recently, GlaxoSmithKline publicized its decision to stop paying doctors to promote its products and try new marketing strategies (Article 1). GlaxoSmithKline's new policy represents an improvement from an ethical point of view because the relationship between the two parties is tainted and is no longer a respectable relationship. This essay examines the obvious aspects of the relationship between the medical profession and pharmaceutical companies, such as GlaxoSmithKline, and its future consequences. The purpose for pharmaceutical companies to interact with doctors is to promote their medical products. In order for companies to reach doctors and leave a memorable impression, they could compensate doctors in the form of gifts and other incentives such as pens and notebooks with the company name. According to the PhRMA code of conduct regarding the interaction between pharmaceutical companies and the medical profession this type of conduct is sufficient (Article 2). Both parties benefit from this type of action, pharmaceutical representatives can have their say, doctors get informed with the latest news on the company's product line and get small rewards that would not have a powerful effect on the human psyche. Moral doctors would promote the drugs that bring the most benefit to their patients and would also take patient feedback into consideration… middle of paper… doctors and drug companies. However there should be some acceptable limits or guidelines to avoid unethical medical practices such as PhRMA code and US law. Unfortunately, these guidelines and regulations have a common disadvantage which is that they can be written and subject to interpretation. Blaming the lack of guidelines or regulations would be inappropriate because it assumes that doctors and pharmaceutical companies are incapable of thinking about whether their actions have ethical implications or are unable to distinguish between right and wrong. It takes two to tango, both teams are wrong. They forgot how their decisions would affect patients. Pharmaceutical companies and doctors must remember that their actions are aimed at better helping humanity and never forget what this power entails..